What do systematic reviews say?

Non‐platinum therapies vs platinum combination

Non‐platinum therapies probably leads to lower 1‐Year survival rate compared with platinum combination (moderate certainty).

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  RR 0.89
  13 studies · 813 participants
  Moderate

Non‐platinum therapies vs platinum combination

Non‐platinum therapies may leads to lower progression‐free survival compared with platinum combination (low certainty).

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  HR 0.76
  9 studies · 9 participants
  Low

Non‐platinum therapies vs platinum combination

Non‐platinum therapies probably leads to higher objective response rate (ORR) compared with platinum combination (moderate certainty).

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  RR 1.57
  11 studies · 1432 participants
  Moderate

Non‐platinum therapies vs platinum combination

Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  RR 2.53
  11 studies · 1437 participants
  Low

Non‐platinum therapies vs platinum combination

Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  RR 3.59
  9 studies · 1260 participants
  Low

Non‐platinum therapies vs platinum combination

Non‐platinum therapies may leads to higher grade 3 or higher Non‐Hematological Toxicity for Platinum‐based… compared with platinum combination (low certainty).

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  RR 7.02
  5 studies · 776 participants
  Low

Non‐platinum therapies vs platinum combination

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 5 participants
  GRADE not reported

Non‐platinum therapies vs platinum combination

Non‐platinum therapies probably leads to lower overall survival compared with platinum combination (moderate certainty).

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  HR 0.76
  13 studies · 13 participants
  Moderate